Medtronic plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Geoffrey Straub Martha
- Full Time Employees
- 95,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Building Two, Parkmore Business Park West Galway GA Ireland H91 4K49
- IPO Date
- May 2, 1973
- CIK
- 0001613103
- Website
- medtronic.com
- Similar Companies
- Business
- Medtronic plc (NYSE: MDT) develops, manufactures, and markets a wide range of medical devices and therapies for the treatment of chronic diseases worldwide. The company offers products across four main segments: cardiovascular (including pacemakers, defibrillators, heart valves, and coronary stents under brands such as Evera, Protecta, and CoreValve); medical surgical (featuring surgical navigation systems, endoscopic tools, and stapling devices like Hugo RAS and Valiant NaviCore); neuroscience (encompassing spinal cord stimulators, deep brain stimulation systems, and intrathecal drug delivery pumps such as Incepta and SynchroMed II); and diabetes (primarily continuous glucose monitoring systems, insulin pumps, and related software through the MiniMed and Guardian brands). Medtronic provides services including patient management software, remote monitoring platforms, and clinical decision support tools to healthcare providers, hospitals, clinics, and patients globally. Founded in 1949 and headquartered in Dublin, Ireland, with principal executive offices in Minneapolis, Minnesota, USA, Medtronic operates in more than 150 countries, serving markets in North America, Europe, Asia-Pacific, Latin America, and the Middle East through direct sales forces, distributors, and subsidiaries. The company targets physicians, hospitals, ambulatory surgery centers, and home care settings, with a focus on minimally invasive therapies and digital health solutions. Key subsidiaries include Covidien (acquired in 2015 for surgical and patient monitoring products) and Intersect ENT (recently integrated for sinus implants). In the past 1-2 years, Medtronic has pursued strategic expansions including the FDA approval and U.S. launch of the Hugo robotic-assisted surgery (RAS) system in 2024 for soft tissue indications, building on its European CE Mark; a multi-year collaboration with NVIDIA announced in 2024 to advance AI-enabled therapies using Medtronic's Gigamon data platform; and the acquisition of Mazor Robotics in 2018 followed by ongoing enhancements to its spinal robotics portfolio with the Mazor X Stealth Edition. The company completed a $4.1 billion acquisition of Covidien assets integration and reported expansions in diabetes care via the Simplera Sync sensor FDA clearance in 2024. Medtronic also announced organizational realignments in 2025 to streamline its four operating units amid portfolio optimization efforts.
Company News
4 Reasons to Buy Medtronic Stock Like There's No Tomorrow
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term
MDT Q1 Earnings Call Focuses on Broad Growth, Raised Guidance
Why Medtronic (MDT) is a Top Growth Stock for the Long-Term
Medtronic Analysts Raise Their Forecasts After Upbeat Q1 Earnings
Společnost Cornerstone Robotics oznamuje strategické partnerství se společností Medtronic s cílem rozšířit globální dostupnost roboticky asistované chirurgie
Cornerstone Robotics ogłasza strategiczne partnerstwo z Medtronic mające na celu zwiększenie dostępu do chirurgii robotycznej na świecie
Medtronic CEO Martha on beating estimates in Q1: Driven by growth across many of our businesses
Medtronic plc (MDT) Q1 2027 Earnings Call Transcript
Medtronic's Stars Are Aligning for a Price Recovery
Wall Street Retreats as Bond Yields Resume Surge
Medtronic Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
Here's What Key Metrics Tell Us About Medtronic (MDT) Q1 Earnings
Medtronic Q1 Earnings Call Highlights
Dow Dips Over 300 Points; Medtronic Shares Gain After Upbeat Q1 Earnings
Medtronic (MDT) Q1 Earnings and Revenues Top Estimates
Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech & Robotics
Medtronic Stock Rises on Better-Than-Expected Earnings and $700 Million Investment in a Robot Surgeon
Medtronic boosts fiscal 2027 forecasts on heart device demand
Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance